PTPRC and plasma cell myeloma: Compared to CD45- myeloma cells, CD45+ myeloma cells with an activated JAK/STAT3 pathway are particularly sensitive to JAK2 inhibitor [54] which inhibits IL-6-induced JAK and STAT3 phosphorylation.